Legal Status This site displays a prototype of a “Web 2.0” version of the daily
Federal Register. It is not an official legal edition of the Federal
Register, and does not replace the official print version or the official
electronic version on GPO’s govinfo.gov.

The documents posted on this site are XML renditions of published Federal
Register documents. Each document posted on the site includes a link to the
corresponding official PDF file on govinfo.gov. This prototype edition of the
daily Federal Register on FederalRegister.gov will remain an unofficial
informational resource until the Administrative Committee of the Federal
Register (ACFR) issues a regulation granting it official legal status.
For complete information about, and access to, our official publications
and services, go to About the Federal Register on NARA's archives.gov.

The OFR/GPO partnership is committed to presenting accurate and reliable
regulatory information on FederalRegister.gov with the objective of
establishing the XML-based Federal Register as an ACFR-sanctioned
publication in the future. While every effort has been made to ensure that
the material on FederalRegister.gov is accurately displayed, consistent with
the official SGML-based PDF version on govinfo.gov, those relying on it for
legal research should verify their results against an official edition of
the Federal Register. Until the ACFR grants it official status, the XML
rendition of the daily Federal Register on FederalRegister.gov does not
provide legal notice to the public or judicial notice to the courts.

Legal Status

Rule

Medications for the Treatment of Opioid Use Disorder; Correction

A Rule by the Health and Human Services Department on 02/23/2026

• 1.

1.

• Document Details Published Content - Document Details Agencies Department of Health and Human Services Office of the Secretary CFR 42 CFR 8 Document Citation 91 FR 8381 Document Number 2026-03577 Document Type Rule Pages 8381-8382
  (2 pages) Publication Date 02/23/2026 RIN 0930-AA39 Published Content - Document Details

• PDF Official Content

  • View printed version (PDF) Official Content

• Document Details Published Content - Document Details Agencies Department of Health and Human Services Office of the Secretary CFR 42 CFR 8 Document Citation 91 FR 8381 Document Number 2026-03577 Document Type Rule Pages 8381-8382
  (2 pages) Publication Date 02/23/2026 RIN 0930-AA39 Published Content - Document Details

• Document Dates Published Content - Document Dates Effective Date 2026-02-23 Dates Text Effective on February 23, 2026. Published Content - Document Dates

• Table of Contents Enhanced Content - Table of Contents This table of contents is a navigational tool, processed from the
  headings within the legal text of Federal Register documents.
  This repetition of headings to form internal navigation links
  has no substantive legal effect.

  • AGENCY:
  • ACTION:
  • SUMMARY:
  • DATES:
  • FOR FURTHER INFORMATION CONTACT:
  • SUPPLEMENTARY INFORMATION:
  • I. Background
  • II. Summary of Errors
  • III. Waiver of Proposed Rulemaking
  • List of Subjects in 42 CFR Part 8
  • PART 8—MEDICATIONS FOR THE TREATMENT OF OPIOID USE DISORDER Enhanced Content - Table of Contents

• Public Comments Enhanced Content - Public Comments Comments are no longer being accepted.
  See DATES for details.

Enhanced Content - Public Comments
- Regulations.gov Data Enhanced Content - Regulations.gov Data Additional information is not currently available for this document.

Enhanced Content - Regulations.gov Data

- Sharing Enhanced Content - Sharing Shorter Document URL https://www.federalregister.gov/d/2026-03577 Email Email this document to a friend Enhanced Content - Sharing

• Print Enhanced Content - Print
  • Print this document Enhanced Content - Print
• Document Statistics Enhanced Content - Document Statistics Document page views are updated periodically throughout the day and are cumulative counts for this document. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.

Page views 215
as of
02/26/2026 at 10:15 am EST Enhanced Content - Document Statistics
- Other Formats Enhanced Content - Other Formats This document is also available in the following formats:

JSON Normalized attributes and metadata XML Original full text XML MODS Government Publishing Office metadata More information and documentation can be found in our developer tools pages.

Enhanced Content - Other Formats
- Public Inspection Public Inspection This PDF is FR Doc. 2026-03577 as it appeared on Public Inspection on
02/20/2026 at 8:45 am.

It was viewed
84
times while on Public Inspection.

If you are using public inspection listings for legal research, you
should verify the contents of the documents against a final, official
edition of the Federal Register. Only official editions of the
Federal Register provide legal notice of publication to the public and judicial notice
to the courts under 44 U.S.C. 1503 & 1507. Learn more here.

Public Inspection
Published Document: 2026-03577 (91 FR 8381) This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Document Headings Document headings vary by document type but may contain
the following:

1. the agency or agencies that issued and signed a document
2. the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to
3. the agency docket number / agency internal file number
4. the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details.

Department of Health and Human Services

Office of the Secretary

1. 42 CFR Part 8
2. RIN 0930-AA39

AGENCY:

Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (HHS).

ACTION:

Correcting amendment.

SUMMARY:

This document corrects two outdated references that should have been deleted and one outdated reference in the final rule that appeared in the February 2, 2024 Federal Register titled “Medications for the Treatment of Opioid Use Disorder,” specifying final modified and updated certain provisions related to Opioid Treatment Program (OTP) accreditation, certification, and standards for the treatment of Opioid Use Disorder with Medications for Opioid Use Disorders in OTPs. The effective date of the final rule was April 2, 2024, and the compliance date was October 2, 2024.

DATES:

Effective on February 23, 2026.

FOR FURTHER INFORMATION CONTACT:

Robert Baillieu, MD, DHSc, MPH, (240) 276-1244, or Robert.Baillieu@samhsa.hhs.gov, Center Substance Abuse Treatment.

SUPPLEMENTARY INFORMATION:

I. Background

In FR Doc. 2024-01693 of February 2, 2024, the Medications for the Treatment of Opioid Use Disorder final rule (89 FR 7528), there were two outdated references that should have been deleted and one outdated reference that is in this correcting document.

II. Summary of Errors

Section 8.3(b) of the regulation erroneously references Accreditation Body application form SMA-167. HHS is correcting the text to reference form SMA-163.

Section 8.11 of the regulation currently links to section 303(g)(1) of the Controlled Substances Act instead of section 303(h), which is the correct reference, and to 42 CFR 8.4(b)(1)(iii), a section which does not exist in the final rule, instead of 42 CFR 8.4(b). HHS is revising the section to replace the outdated text with the correct references.

Publication of this document constitutes final action on these changes under the Administrative Procedure Act (APA) (5 U.S.C. 553). The APA generally exempts rules from the requirements of notice and comment rulemaking when an agency “for good cause finds (and incorporates the finding and a brief statement of reasons therefor in the rules issued) that notice and public procedure thereon are impracticable, unnecessary, or contrary to the public interest” (5 U.S.C. 553(b)(B)).

HHS has determined that notice and public comment are unnecessary because this amendment to the regulation provides only technical or non-substantive changes to specify the location of cross-referenced regulations currently in effect. Such technical, non-substantive changes are “routine determination[s], insignificant in nature and impact, and inconsequential to the industry and to the public.” (Mack Trucks, Inc. v. EPA, 682 F.3d 87, 94 (D.C. Cir. 2012)) (quotation marks and citation omitted). Accordingly, HHS for good cause finds that notice and public procedure thereon are unnecessary for changing this regulation.

In addition, HHS finds good cause for these amendments to become effective on the date of publication of this action. The APA allows an effective date of less than 30 days after publication as “provided by the agency for good cause found and published with the rule” (5 U.S.C. 553(d)(3)). A delayed effective date is unnecessary in this case because the amendments do not impose any new regulatory requirements on affected parties, and affected parties do not need ( printed page 8382) time to “adjust to the new regulation” before the rule takes effect. (Am. Federation of Government Emp., AFL-CIO v. Block, 655 F.2d 1153, 1156 (D.C. Cir. 1981). Therefore, HHS finds good cause for these amendments to become effective on the date of publication of this action.

III. Waiver of Proposed Rulemaking

Section 1871(b)(1) of the Social Security Act (the Act) requires the Secretary to provide for notice of a proposed rule in the Federal Register and provide a period of not less than 60 days for public comment. In addition, section 1871(e)(1)(B)(i) of the Act mandates a 30-day delay in effective date after issuance or publication of a rule. Section 1871(b)(2)(C) of the Act provides an exception from the notice and 60-day comment period and delay in effective date requirements of the Act, under the good cause standard set forth in 5 U.S.C. 553(b)(B).

Section 1871(e)(1)(B)(ii) of the Act provides an exception from the delay in effective date requirements of the Act as well. Section 553(b)(B) authorizes an agency to dispense with normal notice and comment rulemaking procedures for good cause if the agency makes a finding that the notice and comment process is impracticable, unnecessary, or contrary to the public interest, and includes a statement of the finding and the reasons for it in the rule. In addition, section 1871(e)(1)(B)(ii) of the Act allows the agency to avoid the 30-day delay in effective date where the waiver is necessary to comply with statutory requirements, or such delay is contrary to the public interest and the agency includes in the rule a statement of the finding and the reasons for it.

In our view, this correcting document does not constitute a rulemaking that would be subject to these requirements. This document merely corrects typographical errors in the Medications for the Treatment of Opioid Use Disorder final rule. The corrections contained in this document are consistent with, and do not make substantive changes to, the policies and payment methodologies that were proposed, subject to notice and comment procedures, and adopted in the Medications for the Treatment of Opioid Use Disorder final rule. As a result, the corrections made through this document are intended to resolve inadvertent errors so that the Medications for the Treatment of Opioid Use Disorder final rule accurately reflects the policies adopted therein.

In addition, even if this were a rulemaking to which the notice and comment and delayed effective date requirements applied, we find that there is good cause to waive such requirements. Undertaking further notice and comment procedures to incorporate the corrections in this document into the Medications for the Treatment of Opioid Use Disorder final rule or delaying the effective date of the corrections are unnecessary because we are not making any substantive revisions to the Medications for the Treatment of Opioid Use Disorder final rule, but rather, we are simply correcting the Code of Federal Regulations to reflect the policies that we previously proposed, received public comment on, and subsequently finalized in the Medications for the Treatment of Opioid Use Disorder final rule. Further comment is not needed to inform our decision to rectify the ministerial errors noted in this final rule and correction. For these reasons, we believe there is good cause to waive notice and comment and delay in effective date, even if they were required.

List of Subjects in 42 CFR Part 8

• Administrative practice and procedure
• Health professions
• Methadone
• Reporting and recordkeeping requirements
• Substance misuse Accordingly, 42 CFR part 8 is corrected by making the following correcting amendments:

PART 8—MEDICATIONS FOR THE TREATMENT OF OPIOID USE DISORDER

1. The authority citation for part 8 continues to read as follows:

Authority: 21 U.S.C. 823; 42 U.S.C. 257a, 290aa(d), 290dd-2, 300x-23, 300x-27(a), 300y-11.

1. Amend § 8.3 by revising paragraph (b) to read as follows:

§ 8.3 Application for approval as an Accreditation Body. * * * * * (b) Application for initial approval. Electronic copies of an Accreditation Body application form [SMA-163] shall be submitted to: https://dpt2.samhsa.gov/​sma163/.

• * * * * 3. Amend § 8.11 by revising paragraphs (a)(1) and (5) and (c)(3) to read as follows:

§ 8.11 Opioid Treatment Program certification. (a) * * *

(1) An OTP must be the subject of a current, valid certification from the Secretary to be considered qualified by the Secretary under section 303(h) of the Controlled Substances Act (21 U.S.C. 823(h)(1)) to dispense MOUD in the treatment of OUD. An OTP must be determined to be qualified under section 303(h) of the Controlled Substances Act and must be determined to be qualified by the Attorney General under section 303(h), to be registered by the Attorney General to dispense MOUD to individuals for treatment of OUD.

• • * * * (5) OTPs that are certified and are seeking certification renewal, and who have been granted accreditation for 1 year by an Accreditation Body as provided under § 8.4(b), may receive a conditional certification for one year unless the Secretary determines that such conditional certification would adversely affect patient health. An OTP must obtain a standard 3-year certification, as described in paragraph (a)(3) of this section, within the 1-year conditional certification period. If standard accreditation is not obtained by the OTP within the 1-year conditional certification period, the OTP's conditional certification will lapse, and the Attorney General will be notified that the OTP's registration should be revoked.
• • * * * (c) * * *

(3) Within 5 days after it reaches a final determination that an OTP meets the requirements for certification in this section; the Secretary will notify the Drug Enforcement Administration that the OTP has been determined to be qualified to provide OUD treatment under section 303(h) of the Controlled Substances Act.

• * * * * Robert F. Kennedy, Jr.,

Secretary, Department of Health and Human Services.

[FR Doc. 2026-03577 Filed 2-20-26; 8:45 am]

BILLING CODE 4162-20-P

Published Document: 2026-03577 (91 FR 8381)